
Sirnaomics Investor Relations Material
Latest events

H1 2025
29 Aug, 2025

H2 2024
27 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Sirnaomics Ltd
Access all reports
Sirnaomics Ltd is a biopharmaceutical company focused on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. The company specializes in developing RNA-based drugs for the treatment of diseases in areas such as oncology, fibrosis, and other serious conditions. Its platform integrates proprietary delivery technologies designed to enhance the targeting and effectiveness of RNAi-based treatments. Sirnaomics Ltd conducts research, clinical development, and regulatory activities as part of its product advancement strategy. The company is headquartered in Suzhou, China, and its shares are listed on the HKEX.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
2257
Country
🇭🇰 Hong Kong